Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupression

Kidney International

Volumn 71, Issue 12, 2007, Pages 1296-1301

  Gera, M ^a   Griffin, M D ^a   Specks, U ^a   Leung, N ^a   Stegall, M D ^a   Fervenza, F C ^a,b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

ANCA; Kidney transplantation; Microscopic polyangiitis; Relapse; Vasculitis; Wegener

Indexed keywords

ALEMTUZUMAB; ANTIBODY; AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ANCA ASSOCIATED VASCULITIS; ARTICLE; CLINICAL ARTICLE; DRUG SUBSTITUTION; DRUG TOLERABILITY; FEMALE; GINGIVA HYPERPLASIA; GRAFT DYSFUNCTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MICROSCOPIC POLYANGIITIS; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; REMISSION; RISK FACTOR; WEGENER GRANULOMATOSIS;

ADULT; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME; VASCULITIS;

EID: 34250017999     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002244     Document Type: Article

References (37)

1. Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int 2003; 63: 1164-1177.
2. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-192.
3. Falk RJ, Nachman PH, Hogan SL, Jennette JC. ANCA glomerulonephritis and vasculitis: a Chapel Hill perspective. Semin Nephrol 2000; 20: 233-243.
4. Allen A, Pusey C, Gaskin G. Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 1998; 9: 1258-1263.
5. Cohen BA, Clark WF. Pauci-immune renal vasculitis: natural history, prognostic factors, and impact of therapy. Am J Kidney Dis 2000; 36: 914-924.
6. Westman KW, Bygren PG, Olsson H et al. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998; 9: 842-852.
7. Schmitt WH, Van der Woude FJ. Organ transplantation in the vasculitides. Curr Opin Rheumatol 2003; 15: 22-28.
8. Wolfe RA, Ashby VB, Milford EL et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725-1730.
9. Schnuelle P, Lorenz D, Trede M, van Der Woude FJ. Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J Am Soc Nephrol 1998; 9: 2135-2141.
10. Fauci AS, Balow JE, Brown R et al. Successful renal transplantation in Wegener's granulomatosis. Am J Med 1976; 60: 437-440.
11. Lyons GW, Lindsay WG. Renal transplantation in a patient with Wegener's granulomatosis. Am J Surg 1972; 124: 104-107.
12. Moises J, Torregrosa JV, Ybarra J, Oppenheimer F. Renal transplantation in a C-ANCA(+) patient with Behcet disease and rapidly progressive glomerulonephritis. Clin Nephrol 2004; 61: 357-359.
13. Besbas N, Ozaltin F, Tinaztepe K et al. Successful renal transplantation in a child with ANCA-associated microscopic polyangiitis. Pediatr Nephrol 2003; 18: 696-699.
14. Frasca GM, Neri L, Martello M et al. Renal transplantation in patients with microscopic polyarteritis and antimyeloperoxidase antibodies: report of three cases. Nephron 1996; 72: 82-85.
15. Grotz W, Wanner C, Rother E, Schollmeyer P. Clinical course of patients with antineutrophil cytoplasm antibody positive vasculitis after kidney transplantation. Nephron 1995; 69: 234-236.
16. Haubitz M, Kliem V, Koch KM et al. Renal transplantation for patients with autoimmune diseases: single-center experience with 42 patients. Transplantation 1997; 63: 1251-1257.
17. Kuross S, Davin T, Kjellstrand CM. Wegener's granulomatosis with severe renal failure: clinical course and results of dialysis and transplantation. Clin Nephrol 1981; 16: 172-180.
18. Rostaing L, Modesto A, Oksman F et al. Outcome of patients with antineutrophil cytoplasmic autoantibody-associated vasculitis following cadaveric kidney transplantation. Am J Kidney Dis 1997; 29: 96-102.
19. Schmitt WH, Haubitz M, Mistry N et al. Renal transplantation in Wegener's granulomatosis. Lancet 1993; 342: 860.
20. Wrenger E, Pirsch JD, Cangro CB et al. Single-center experience with renal transplantation in patients with Wegener's granulomatosis. Transpl Int 1997; 10: 152-156.
21. Clarke AE, Bitton A, Eappen R et al. Treatment of Wegener's granulomatosis after renal transplantation: is cyclosporine the preferred treatment? Transplantation 1990; 50: 1047-1051.
22. Nachman PH, Segelmark M, Westman K et al. Recurrent ANCA-associated small vessel vasculitis after transplantation: a pooled analysis. Kidney Int 1999; 56: 1544-1550.
23. Deegens JK, Artz MA, Hoitsma AJ, Wetzels JF. Outcome of renal transplantation in patients with pauci-immune small vessel vasculitis or anti-GBM disease. Clin Nephrol 2003; 59: 1-9.
24. Schmitt WH, Opelz G, van der Woude FJ. Renal transplantation is safe and successful in Wegener's granulomatosis: data from the Collaborative Transplant Study. J Am Soc Nephrol 2002; 13: 564A-565A.
25. Elmedhem A, Adu D, Savage CO. Relapse rate and outcome of ANCA-associated small vessel vasculitis after transplantation. Nephrol Dial Transplant 2003; 18: 1001-1004.
26. Harper L, Savage CO. Pathogenesis of ANCA-associated systemic vasculitis. J Pathol 2000; 190: 349-359.
27. Ludviksson BR, Sneller MC, Chua KS et al. Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J Immunol 1998; 160: 3602-3609.
28. Schmitt WH, Hagen EC, Neumann I et al. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 2004; 65: 1440-1448.
29. Browne BJ. The tricontinental mycophenolate mofetil trial. Transplantation 1996; 62: 1697.
30. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225-232.
31. Stegeman CA, Cohen Tervaert JW. Mycophenolate mofetil for remission induction in patients with active Wegener's granulomatosis intolerant of cyclophosphamide. J Am Soc Nephrol 2000; 11: 159A.
32. Nowack R, Gobel U, Klooker P et al. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999; 10: 1965-1971.
33. Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004; 51: 278-283.
34. Joy MS, Hogan SL, Jennette JC et al. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant 2005; 20: 2725-2732.
35. Chabdan SJ. Glomerulonephritis recurrence in the renal graft. J Am Soc Nephrol 2001; 12: 394-402.
36. Leavitt RY, Fauci AS, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33: 1101-1107.
37. Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7: 33-39.